SCHEMBL874819

SCHEMBL874819

Cc1ccc(C(=O)Nc2ccc(S(=O)(=O)C(CCn3nnc4cc(C)ccc4c3=O)C(=O)O)cc2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR139 Q6DWJ6 3/20 0.44
HTT P42858 1/20 0.43
RAB9A P51151 2/20 0.43
MMP9 P14780 3/20 0.42
MMP2 P08253 2/20 0.42
MMP3 P08254 1/20 0.41
MMP13 P45452 1/20 0.41
KMT2A Q03164 4/20 0.40
MEN1 O00255 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
ALDH1A1 P00352 2/20 0.40
HPGD P15428 2/20 0.40
HSD17B10 Q99714 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
LMNA P02545 2/20 0.39
MAPT P10636 2/20 0.39
MAPK1 P28482 1/20 0.39
POLB P06746 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL875092 0.93 GPR139 (0.44) GPR139HTTRAB9AMMP9MMP2
SCHEMBL874410 0.92 HTT (0.54) GPR139HTTRAB9AMMP9MMP2
SCHEMBL874946 0.89 CTNNB1 (0.43) GPR139HTTMMP9MMP2KMT2A
SCHEMBL874269 0.89 CTNNB1 (0.43) GPR139HTTRAB9AMMP9MMP2
SCHEMBL875236 0.88 MAPT (0.45) GPR139HTTRAB9AMMP9MMP2
SCHEMBL874966 0.87 GPR139 (0.49) GPR139RAB9AMMP9MMP2MMP3
SCHEMBL875435 0.87 GPR139 (0.49) GPR139HTTRAB9AMMP9MMP2
SCHEMBL875017 0.86 HTT (0.47) GPR139HTTKMT2AMEN1SMN1; SMN2
SCHEMBL878389 0.86 CTNNB1 (0.45) GPR139HTTRAB9APOLB
SCHEMBL874492 0.85 KMT2A (0.49) HTTMMP9MMP2MMP3MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140148459-A1 MATRIX METALLOPROTEINASE INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2014-05-29 US claimed
US-20140148459-A1 MATRIX METALLOPROTEINASE INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2014-05-29 US disclosed
EP-2619185-A1 MATRIX METALLOPROTEINASE INHIBITORS Ranbaxy Laboratories Limited (IN) 2013-07-31 EP disclosed
WO-2012038942-A1 MATRIX METALLOPROTEINASE INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2012-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140148459-A1 MATRIX METALLOPROTEINASE INHIBITORS MMP9, MMP12, MMP10 GPR139 2694/4885HTT 4338/4885RAB9A 1310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.